Aptinyx (APTX) Appoints Gilmore O’Neill to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- AppLovin gains market share among e-commerce advertisers
- Wall Street ends higher as investors turn to earnings season
Aptinyx Appoints Gilmore O’Neill, M.B., M.M.Sc., to Board of Directors
October 20, 2021 7:57 AM EDTEVANSTON, Ill.--(BUSINESS WIRE)-- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore ONeill, M.B., M.M.Sc., to the companys board of directors. Dr. ONeill currently serves as chief medical officer and executive vice president of research and development at Sarepta Therapeutics.
Gilmore brings an exceptional background of experience and leadership to the Aptinyx board of directors, said Norbert Riedel, Ph.D., chief executive officer of Aptinyx. His expertise in research and clinical... More
